These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 10778846)

  • 21. [The HOPE Study. What does it contribute to general practice?].
    Mann J; Sleight P
    MMW Fortschr Med; 2000 Nov; 142(47):28-32. PubMed ID: 11143776
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Efficacy of angiotensin-converting enzyme inhibitors in secondary prevention].
    Ceconi C; Mastrorilli F; Squasi PA; Gaitani S; Guardigli G; Ferrari R
    Ital Heart J; 2005 Nov; 6 Suppl 7():5S-13S. PubMed ID: 16485512
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Experiences with the realisation of the innovative study designs using the example of the HOPE study -- concerning the contribution in DMW Supplement 2/2005].
    Traut V
    Dtsch Med Wochenschr; 2005 Nov; 130(47):2726; author reply 2727-8. PubMed ID: 16294292
    [No Abstract]   [Full Text] [Related]  

  • 24. ACE inhibition in cardiovascular disease.
    Francis GS
    N Engl J Med; 2000 Jan; 342(3):201-2. PubMed ID: 10639547
    [No Abstract]   [Full Text] [Related]  

  • 25. Tissue angiotensin-converting enzyme inhibitors for the prevention of cardiovascular disease in patients with diabetes mellitus without left ventricular systolic dysfunction or clinical evidence of heart failure: a pooled meta-analysis of randomized placebo-controlled clinical trials.
    Saha SA; Molnar J; Arora RR
    Diabetes Obes Metab; 2008 Jan; 10(1):41-52. PubMed ID: 18095949
    [TBL] [Abstract][Full Text] [Related]  

  • 26. What is the relevance of the HOPE study in general practice?
    Kennedy J; Mogensen CE; Ball SG; Castaigne AD; Commerford PJ; Distiller L; Fisher BM; Gonzalez-Jaunatey J; Nosadini R; Novials A; Ostergren J; Palma-Gámiz J; Perrone-Filardi P; Schipperheijn JJ; Senges J; Trevisan R
    Int J Clin Pract; 2001 Sep; 55(7):449-57. PubMed ID: 11594254
    [TBL] [Abstract][Full Text] [Related]  

  • 27. More than just hype.
    Fitchett D
    CMAJ; 2003 Jun; 168(13):1646-7; author reply 1647-8. PubMed ID: 12821613
    [No Abstract]   [Full Text] [Related]  

  • 28. [Atherosclerosis. High ACE activity in plaque: risk of rupture!].
    MMW Fortschr Med; 2001 Oct; 143(43):51. PubMed ID: 11715882
    [No Abstract]   [Full Text] [Related]  

  • 29. Should you take an ACE inhibitor?
    Johns Hopkins Med Lett Health After 50; 2000 Mar; 12(1):1-2. PubMed ID: 10740441
    [No Abstract]   [Full Text] [Related]  

  • 30. Use of angiotensin-converting enzyme inhibitor/angiotensin receptor blocker therapy to reduce cardiovascular events in high-risk patients: part 2.
    Bommer WJ
    Prev Cardiol; 2008; 11(4):215-22. PubMed ID: 19476574
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Type 2 diabetes and cardiovascular risk: lessons from therapeutic trials].
    Lièvre M
    Rev Prat; 2001 Oct; 51(16):1793-9. PubMed ID: 11795124
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long-term effects of ramipril on cardiovascular events and on diabetes: results of the HOPE study extension.
    Bosch J; Lonn E; Pogue J; Arnold JM; Dagenais GR; Yusuf S;
    Circulation; 2005 Aug; 112(9):1339-46. PubMed ID: 16129815
    [TBL] [Abstract][Full Text] [Related]  

  • 33. More than just hype.
    Yusuf S; Dagenais G
    CMAJ; 2003 Jun; 168(13):1646; author reply 1647-8. PubMed ID: 12821614
    [No Abstract]   [Full Text] [Related]  

  • 34. Microalbuminuria and tubular proteinuria as risk predictors of cardiovascular morbidity and mortality in essential hypertension: final results of a prospective long-term study (MARPLE Study)*.
    Schrader J; Lüders S; Kulschewski A; Hammersen F; Züchner C; Venneklaas U; Schrandt G; Schnieders M; Rangoonwala B; Berger J; Dominiak P; Zidek W;
    J Hypertens; 2006 Mar; 24(3):541-8. PubMed ID: 16467658
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Blood pressure and cardiovascular risk in the HOPE study.
    Taylor R
    Lancet; 2002 Jun; 359(9323):2117-8; author reply 2118. PubMed ID: 12086795
    [No Abstract]   [Full Text] [Related]  

  • 36. The ADVANCE trial.
    Procopiou M
    Lancet; 2008 Jan; 371(9606):25; author reply 26. PubMed ID: 18177767
    [No Abstract]   [Full Text] [Related]  

  • 37. Ramipril use in Canada: HOPE or HYPE?
    Pilote L
    CMAJ; 2003 Mar; 168(5):568-9. PubMed ID: 12615751
    [No Abstract]   [Full Text] [Related]  

  • 38. A safe new dose of heart protection. Study shows drug can prevent attacks, strokes.
    Comarow A
    US News World Rep; 1999 Nov; 127(20):76. PubMed ID: 10623306
    [No Abstract]   [Full Text] [Related]  

  • 39. [Effect of a converting enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients].
    Hébert M
    Presse Med; 2000 Apr; 29(14):790-2. PubMed ID: 10816721
    [No Abstract]   [Full Text] [Related]  

  • 40. [Clinical study of the month. The HOPE study, a two-by-two factorial clinical trial with contrasted results].
    Scheen AJ
    Rev Med Liege; 2000 Feb; 55(2):121-4. PubMed ID: 10769584
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.